Meeting News Coverage

ATLAS study: Treat-and-extend with aflibercept reduces AMD treatment burden

SAN FRANCISCO — Treat-and-extend aflibercept therapy for neovascular age-related macular degeneration improved vision and significantly reduced the treatment burden at 2 years, according to a scientific poster presented by David C. Reed, MD, and colleagues at the American Society of Retina Specialists meeting.

The prospective, multicenter, open-label ATLAS study included 40 eyes of 40 patients treated every 4 weeks with Eylea (aflibercept, Regeneron) until no signs of macular exudation were visible.

Treatment interval in year 1 was 12 weeks in 26% of patients. In year 2, the interval was 8 weeks in 32% of patients. At 2 years, median improvement in vision per protocol was eight letters. Visual acuity was 20/40 or better in 40% of patients.

No ocular or systemic adverse events were identified. – by Matt Hasson

Editor's note: This article has been updated to correct treatment interval data.

Reference:

Reed DC, et al. Prospective, multicenter study of aflibercept treat and extend therapy for neovascular age-related macular degeneration using the ATLAS protocol: one and two year results. Presented at: American Society of Retina Specialists annual meeting; Aug. 9-14, 2016. San Francisco.

Disclosure: Reed reports he is a consultant for Regeneron.

SAN FRANCISCO — Treat-and-extend aflibercept therapy for neovascular age-related macular degeneration improved vision and significantly reduced the treatment burden at 2 years, according to a scientific poster presented by David C. Reed, MD, and colleagues at the American Society of Retina Specialists meeting.

The prospective, multicenter, open-label ATLAS study included 40 eyes of 40 patients treated every 4 weeks with Eylea (aflibercept, Regeneron) until no signs of macular exudation were visible.

Treatment interval in year 1 was 12 weeks in 26% of patients. In year 2, the interval was 8 weeks in 32% of patients. At 2 years, median improvement in vision per protocol was eight letters. Visual acuity was 20/40 or better in 40% of patients.

No ocular or systemic adverse events were identified. – by Matt Hasson

Editor's note: This article has been updated to correct treatment interval data.

Reference:

Reed DC, et al. Prospective, multicenter study of aflibercept treat and extend therapy for neovascular age-related macular degeneration using the ATLAS protocol: one and two year results. Presented at: American Society of Retina Specialists annual meeting; Aug. 9-14, 2016. San Francisco.

Disclosure: Reed reports he is a consultant for Regeneron.

    See more from American Society of Retina Specialists Meeting